Seres Therapeutics, Inc. (MCRB)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
8.89 USD
+0.06
(0.680%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.89 Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:25 p.m. EDT
Despite the optimistic analyst target of $22 and positive long-term catalysts, Seres Therapeutics faces an imminent catastrophic short-term outlook. The company has paused its lead drug study (SER-155 Phase 2) and executed a 30% workforce reduction to conserve cash, eroding confidence in the pipeline's near-term viability. With a short ratio of 12.5x and negative earnings, the stock is technically in a downtrend below both 50-day and 200-day averages. The combination of halted clinical progress, massive headcount cuts, and deteriorating metrics makes this a 'sell' situation for income investors and a high-risk turnaround bet for growth investors, not a buy. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.452569 |
| AutoETS | 0.459096 |
| AutoTheta | 0.459216 |
| AutoARIMA | 0.506155 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 2.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 187.629 |
| Revenue per Share | 0.089 |
| Market Cap | 85,222,192 |
| Trailing P/E | 13.89 |
| Forward P/E | -0.97 |
| Beta | 0.26 |
| Profit Margins | 721.93% |
| Website | https://www.serestherapeutics.com |
As of April 18, 2026, 10:25 p.m. EDT: Options activity highlights mixed conflicting signals with a defensive bias. Call data shows significant Open Interest concentrated 125%+ above ATM ($30 and $30 strikes for April/July) but extremely low volume, indicating synthetic long exposure or hedging rather than pure bullish bets. Conversely, Put Open Interest at deep ITM strikes ($12.5, $20, $30 for April) is substantial, acting as a high put-flat or crash hedge. The realized IV for these high strikes is extremely suppressed (0.0-$0.030) implying a lack of liquidity and aggressive pricing inefficiency. The skew suggests speculators are hedging a downside event or betting on a mega-move, rather than a standard bullish trend.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.18850267 |
| Address1 | 101 Cambridgepark Drive |
| All Time High | 1,040.0 |
| All Time Low | 6.53 |
| Ask | 11.26 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 44,950 |
| Average Daily Volume3 Month | 66,079 |
| Average Volume | 66,079 |
| Average Volume10Days | 44,950 |
| Beta | 0.262 |
| Bid | 6.41 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 4.627 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.89 |
| Current Ratio | 2.555 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 9.105 |
| Day Low | 8.67 |
| Debt To Equity | 187.629 |
| Display Name | Seres Therapeutics |
| Earnings Call Timestamp End | 1,762,349,400 |
| Earnings Call Timestamp Start | 1,762,349,400 |
| Earnings Timestamp | 1,773,318,600 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | -89,838,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.363 |
| Enterprise To Revenue | 155.161 |
| Enterprise Value | 122,422,192 |
| Eps Current Year | -8.23 |
| Eps Forward | -9.17 |
| Eps Trailing Twelve Months | 0.64 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.3339 |
| Fifty Day Average Change | -0.4439001 |
| Fifty Day Average Change Percent | -0.047557835 |
| Fifty Two Week Change Percent | 18.850267 |
| Fifty Two Week High | 29.98 |
| Fifty Two Week High Change | -21.09 |
| Fifty Two Week High Change Percent | -0.703469 |
| Fifty Two Week Low | 6.53 |
| Fifty Two Week Low Change | 2.3600001 |
| Fifty Two Week Low Change Percent | 0.3614089 |
| Fifty Two Week Range | 6.53 - 29.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,435,325,400,000 |
| Float Shares | 7,284,149 |
| Forward Eps | -9.17 |
| Forward P E | -0.9694657 |
| Free Cashflow | -54,955,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 66 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -54,815,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11829001 |
| Held Percent Institutions | 0.25629 |
| Implied Shares Outstanding | 9,586,298 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,745,280,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Seres Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 85,222,192 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_222388947 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 5,696,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 84,934,600 |
| Number Of Analyst Opinions | 1 |
| Open | 8.67 |
| Operating Cashflow | 1,117,000 |
| Operating Margins | -44.23973 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 945 9626 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.89 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 8.83 |
| Price Eps Current Year | -1.0801945 |
| Price Hint | 2 |
| Price To Book | 1.9213314 |
| Price To Sales Trailing12 Months | 108.01292 |
| Profit Margins | 7.21926 |
| Quick Ratio | 2.395 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0600004 |
| Regular Market Change Percent | 0.679506 |
| Regular Market Day High | 9.105 |
| Regular Market Day Low | 8.67 |
| Regular Market Day Range | 8.67 - 9.105 |
| Regular Market Open | 8.67 |
| Regular Market Previous Close | 8.83 |
| Regular Market Price | 8.89 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 105,118 |
| Return On Assets | -0.42253 |
| Return On Equity | 0.19641 |
| Revenue Per Share | 0.089 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 9,586,298 |
| Shares Percent Shares Out | 0.0623 |
| Shares Short | 597,314 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 655,113 |
| Short Name | Seres Therapeutics, Inc. |
| Short Percent Of Float | 0.096099995 |
| Short Ratio | 12.51 |
| Source Interval | 15 |
| State | MA |
| Symbol | MCRB |
| Target High Price | 22.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 22.0 |
| Target Median Price | 22.0 |
| Total Cash | 45,766,000 |
| Total Cash Per Share | 4.774 |
| Total Debt | 82,966,000 |
| Total Revenue | 789,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.64 |
| Trailing P E | 13.890626 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.731775 |
| Two Hundred Day Average Change | -5.841775 |
| Two Hundred Day Average Change Percent | -0.3965425 |
| Type Disp | Equity |
| Volume | 105,118 |
| Website | https://www.serestherapeutics.com |
| Zip | 2,140 |